Skip to main content
. Author manuscript; available in PMC: 2015 Jan 1.
Published in final edited form as: Psychosom Med. 2013 Dec 23;76(1):29–37. doi: 10.1097/PSY.0000000000000022

Table 1.

Participant Characteristics by Treatment Group and Baseline Cardiovascular (CVD) Status (N = 235)

Characteristic No Baseline CVD Baseline CVD

IMPACT (n = 85) Usual Care (n = 83) p value IMPACT (n = 35) Usual Care (n = 32) p value
Demographic Factors
 Age (years), mean (SD) 66.8 (6.3) 67.8 (6.6) .33 67.9 (6.9) 67.8 (7.8) .97
 Male, % 18.8 22.9 .52 31.4 31.2 .99
 African-American, % 42.4 53.0 .17 45.7 46.9 .92
Baseline Cardiovascular Risk Factors
 Hypertension, % 68.2 75.9 .27 91.4 78.1 .13
 Diabetes, % 34.1 34.9 .91 40.0 43.8 .76
 Smoker, % 29.4 41.0 .12 28.6 31.2 .81
 Body-Mass Index (kg/m2), mean (SD) 33.2 (10.0) 30.5 (9.5) .066 31.2 (9.1) 30.3 (8.2) .67
Baseline Depression Variables
 MDD only, % 12.9 10.8 .67 17.1 6.2 .17
 Dysthymia only, % 36.5 38.6 .78 37.1 37.5 .98
 MDD and Dysthymia, % 50.6 50.6 .99 45.7 56.3 .39
 SCL-20 score, mean (SD) (range: 0–4) 1.4 (0.5) 1.5 (0.5) .17 1.5 (0.5) 1.8 (0.5) .070
 Antidepressant Use in Past 3 Months, % 51.8 48.2 .64 48.6 59.4 .38
Depression Outcomes and Care
 SCL-20 Change, mean (SD) −0.4 (0.7) 0.1 (0.6) <.001 −0.2 (0.6) −0.1 (0.8) .83
 Antidepressants during the trial, % 75.3 60.2 .037 79.4 83.9 .64
 Psychotherapy during the trial, % 62.4 14.5 <.001 58.8 25.8 .007

Note. Independent samples t tests were used to compare groups on age, baseline SCL-20, and SCL-20 change (12-month score –baseline score). All other group comparisons were made using chi-square tests. IMPACT = Improving Mood-Promoting Access to Collaborative Treatment. MDD = major depressive disorder. SCL-20 = Symptom Checklist-20.

Because only 6 (3%) patients and 4 (2%) patients fell into the Hispanic and Other categories, respectively, we created a dichotomous race variable (0 = White, Hispanic, and Other; 1 = African American).